Brian Stephens
Optometrist · Phoenix, AZNPI 1144219825
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,024 of the $6,963 with a category attached, or 86.5%. It is spread thinly across 29 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$942
- Notal Vision, Inc.$931
- Alcon$665
- Novartis$538
- Bausch & Lomb Americas Inc.$515
- Sun Pharmaceutical Industries Inc.$480
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$93113%
- Food & beverage$6,02487%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $942 |
| Notal Vision, Inc. | 5 | $931 |
| Alcon | 15 | $665 |
| Novartis | 38 | $538 |
| Bausch & Lomb Americas Inc. | 17 | $515 |
| Sun Pharmaceutical Industries Inc. | 24 | $480 |
| Glaukos Corporation | 3 | $392 |
| Tarsus Pharmaceuticals, Inc. | 8 | $352 |
| Dompe US, Inc. | 9 | $326 |
| Kala Pharmaceuticals, Inc. | 17 | $315 |
| Harrow Eye, LLC | 7 | $204 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $167 |
| Oyster Point Pharma, Inc. | 8 | $150 |
| Mallinckrodt Enterprises LLC | 8 | $146 |
| Mallinckrodt Hospital Products Inc. | 5 | $126 |
| Sight Sciences, Inc. | 5 | $91 |
| Regeneron Healthcare Solutions, Inc. | 3 | $91 |
| Amgen(2 entities) | 5 | $87 |
| Shire North American Group Inc | 5 | $84 |
| Astellas Pharma US Inc | 3 | $79 |
| Tearlab Corp | 3 | $46 |
| Biotissue Holdings Inc. | 2 | $44 |
| Thea Pharma Inc. | 2 | $41 |
| Genentech USA, Inc. | 1 | $34 |
| Aerie Pharmaceuticals, Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Alimera Sciences, Inc. | 1 | $23 |
| Lumenis, Inc | 1 | $19 |
| Rxsight Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,963 in reported general payments places this provider in the 95th percentile of 1,134 optometrist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 26 | $1,098,271 |
| RestasisCyclosporine | 310 | $337,826 |
| XiidraLifitegrast | 84 | $95,694 |
| LumiganBimatoprost | 142 | $80,039 |
| Cyclosporine | 110 | $52,252 |
| VyzultaLatanoprostene Bunod | 56 | $27,613 |
| TyrvayaVarenicline Tartrate | 41 | $25,810 |
| XdemvyLotilaner | 11 | $21,855 |
| RocklatanNetarsudil Mesylat/Latanoprost | 37 | $18,830 |
| MieboPerfluorohexyloctane/Pf | 25 | $18,334 |
| Prednisolone Acetate | 481 | $14,146 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $12,422 |
| RhopressaNetarsudil Mesylate | 14 | $10,249 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $9,238 |
| Fluorometholone | 82 | $6,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $326 | $1,098,27126 claims |
| AbbVieRestasis, Lumigan, Combigan | $942 | $430,287484 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $515 | $141,641165 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $33 | $29,07951 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $150 | $25,81041 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $352 | $21,85511 claims |
| AlconSimbrinza | $665 | $9,23825 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $167 | $2,09819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,134 optometrist providers in Arizona.
Other optometrist in Phoenix
- Debbie DuongPhoenix$14K
- Shannon SteinhauserPhoenix$13K
- Simon ZmyslinskiPhoenix$12K
- Ric RiosPhoenix$12K
- Stephanie MastoresPhoenix$11K
- Allissun HoppertPhoenix$10K
- Keyla GammaranoPhoenix$10K
- Randall PaulPhoenix$10K
- Amanda MisincoPhoenix$8K
- Amy CzyzPhoenix$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.